Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, et al. Breast Cancer Res Treat 2021 May 4. pii: 10.1007/s10549-021-06235.

Read + Share

Amedeo Smart

Independent Medical Education

Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, et al. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Res Treat 2021 May 4. pii: 10.1007/s10549-021-06235.
PMID: 33945043